Joanna M Young

Summary

Country: New Zealand

Publications

  1. ncbi request reprint Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure
    Christopher H Strey
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Atherosclerosis 179:201-6. 2005
  2. doi request reprint Pharmacokinetic comparison of a generic coenzyme Q₁₀ solubilizate and a formulation with soybean phytosterols
    Joanna M Young
    Lipid and Diabetes Research Group, Diabetes Research Institute, Christchurch Hospital Campus, Private Bag 4710, Christchurch, New Zealand
    Phytother Res 26:1092-6. 2012
  3. doi request reprint A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome
    Joanna M Young
    Lipid and Diabetes Research Group, Diabetes Research Institute, Christchurch Hospital Campus, New Zealand
    Am J Hypertens 25:261-70. 2012
  4. doi request reprint Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy
    Joanna M Young
    Lipid and Diabetes Research Group, Diabetes Research Institute, Christchurch Hospital Campus, Private Bag 4710, Christchurch 8011, New Zealand
    Atherosclerosis 218:188-93. 2011
  5. ncbi request reprint Comparative effects of enzogenol and vitamin C supplementation versus vitamin C alone on endothelial function and biochemical markers of oxidative stress and inflammation in chronic smokers
    Joanna M Young
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Free Radic Res 40:85-94. 2006
  6. ncbi request reprint Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia
    Joanna M Young
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Am J Cardiol 100:1400-3. 2007
  7. doi request reprint Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure
    Joanna M Young
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Eur J Heart Fail 10:463-6. 2008
  8. ncbi request reprint Coenzyme Q10; an adjunctive therapy for congestive heart failure?
    Sarah L Molyneux
    Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    N Z Med J 122:74-9. 2009
  9. pmc Coenzyme Q10: is there a clinical role and a case for measurement?
    Sarah L Molyneux
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Clin Biochem Rev 29:71-82. 2008
  10. pmc Heart Fatty Acid Binding Protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction
    Joanna M Young
    University of Otago, Christchurch, New Zealand
    BMC Emerg Med 16:34. 2016

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure
    Christopher H Strey
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Atherosclerosis 179:201-6. 2005
    ..Further studies are required to determine whether coenzyme Q(10) reductions are limiting the maximum favourable effects of statin therapy on the microcirculation...
  2. doi request reprint Pharmacokinetic comparison of a generic coenzyme Q₁₀ solubilizate and a formulation with soybean phytosterols
    Joanna M Young
    Lipid and Diabetes Research Group, Diabetes Research Institute, Christchurch Hospital Campus, Private Bag 4710, Christchurch, New Zealand
    Phytother Res 26:1092-6. 2012
    ..74). The combined CoQ₁₀ and phytosterol formulation, SterolQ₁₀, showed bioequivalence to the generic CoQ₁₀ following a single CoQ₁₀ dose, and demonstrated comparable bioavailability following multiple dose administration...
  3. doi request reprint A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome
    Joanna M Young
    Lipid and Diabetes Research Group, Diabetes Research Institute, Christchurch Hospital Campus, New Zealand
    Am J Hypertens 25:261-70. 2012
    ..Our aim was to examine the effects of adjunctive coenzyme Q(10) therapy on 24-h ambulatory blood pressure (BP) in subjects with the metabolic syndrome and inadequate BP control...
  4. doi request reprint Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy
    Joanna M Young
    Lipid and Diabetes Research Group, Diabetes Research Institute, Christchurch Hospital Campus, Private Bag 4710, Christchurch 8011, New Zealand
    Atherosclerosis 218:188-93. 2011
    ....
  5. ncbi request reprint Comparative effects of enzogenol and vitamin C supplementation versus vitamin C alone on endothelial function and biochemical markers of oxidative stress and inflammation in chronic smokers
    Joanna M Young
    Lipid and Diabetes Research Group, Christchurch Hospital, New Zealand
    Free Radic Res 40:85-94. 2006
    ..However, Enzogenol did demonstrate additional favourable effects on protein oxidative damage and fibrinogen levels...
  6. ncbi request reprint Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia
    Joanna M Young
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Am J Cardiol 100:1400-3. 2007
    ..47). In conclusion, coenzyme Q(10) supplementation did not improve statin tolerance or myalgia, although further studies are warranted...
  7. doi request reprint Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure
    Joanna M Young
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Eur J Heart Fail 10:463-6. 2008
    ..Since statins upregulate eNOS and ameliorate endothelial dysfunction in non-ischaemic CHF, we hypothesized that this may be in part through modification of ADMA...
  8. ncbi request reprint Coenzyme Q10; an adjunctive therapy for congestive heart failure?
    Sarah L Molyneux
    Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    N Z Med J 122:74-9. 2009
    ..CoQ10 depletion may also be a contributory factor for why statin intervention has not improved outcomes in CHF. There is an emerging evidence base in support of CoQ10 as an adjunctive therapy in CHF...
  9. pmc Coenzyme Q10: is there a clinical role and a case for measurement?
    Sarah L Molyneux
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Clin Biochem Rev 29:71-82. 2008
    ..Emerging evidence will determine whether CoQ(10) does indeed have an important clinical role and in particular, whether there is a case for measurement...
  10. pmc Heart Fatty Acid Binding Protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction
    Joanna M Young
    University of Otago, Christchurch, New Zealand
    BMC Emerg Med 16:34. 2016
    ..We assessed a new commercial Heart Fatty Acid Binding Protein (H-FABP) assay for additional diagnostic value when combined with cardiac troponin (using a high sensitivity assay)...
  11. doi request reprint Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within Practice
    Martin P Than
    Christchurch Hospital, Christchurch, New Zealand Electronic address
    Ann Emerg Med 68:93-102.e1. 2016
    ..This trial tests for the existence and size of any beneficial effect of using the EDACS-ADP in routine clinical care...
  12. doi request reprint The utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department
    John W Pickering
    Emergency Department, Christchurch Hospital, Christchurch, New Zealand University of Otago, Christchurch, New Zealand
    Clin Biochem 48:1219-24. 2015
    ..The background evidence for this approach is limited. We evaluated whether on presentation and 4-hour high-sensitivity troponin I (hs-cTnI) could be used to accurately rule-out AMI...